recursion pharmaceuticals ipo
Sign up. Recursion will use between $65 million and $85 million to bankroll the development of its four clinical programs. After initially indicating it intended to raise $100 … Username or Email. Recursion Publishes First Environmental, Social and Governance (ESG) Report. The stock is set to debut on the … After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million.. Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the … Company Name: Recursion Pharmaceuticals Stock Symbol: RXRX Exchange: NASDAQ Status: Priced IPO Date: 4/16/2021 IPO Price: 18.00 … By Josh Beckerman . Davis Polk advised the representatives of the several underwriters in connection with the $500 million initial public offering of 27,878,787 shares of Class A common stock of Recursion Pharmaceuticals, Inc. Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital. Recursion Pharmaceuticals Inc. uses machine learning to hunt for new therapies. (Bloomberg) -- Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, rose 74% in its trading debut after exceeding goals for its initial public offering to raise $436 million. But Recursion Pharmaceuticals, one of the oldest and most established AI drug discovery companies, has found a way to stand out. IPO: Recursion Pharmaceuticals Leverages Therapeutics Discovery With Machine Learning. Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing. Recursion Pharmaceuticals Expands IPO to Raise $436 Million. The company, which will trade under the ticker symbol “RXRX,” will sell 18 million … We were formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC. The minimum investment amount is $2,000. Username or Email. Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. The company completed its IPO [NASDAQ: RXRX] in 2021. The company priced 24.2 million shares of its Class A common stock at $18 per share. We advised the underwriters on the IPO and Nasdaq listing. Recursion Pharmaceuticals, Inc. Facebook Twitter. (RXRX) raised $306 million in an initial public offering on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. What is Recursion Pharmaceuticals' stock symbol? Leaps by Bayer and Advantage Capital are the most recent investors. IPO: Recursion Pharmaceuticals Leverages Therapeutics Discovery With Machine Learning. Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file. Client: Recursion Pharmaceuticals Campaign: IPO Road Show Videos Need Recursion Pharma is a biotech company that uses AI to develop drugs for rare diseases. April 16, 2021 - 12:13 am. Founded in 2013, Recursion Pharma is a clinical-stage technology -enabled drug discovery company. View Mark Stafford Smith’s profile on LinkedIn, the world’s largest professional community. Benevolent AI is planning to go public using a SPAC (ugh), while Insilico is said to have filed confidentially for an IPO. Do NOT follow this link! You can find Recursion Pharmaceuticals, Inc. Security Issue Memo on the SEC website. SVB Leerink downgraded Recursion Pharmaceuticals from an “outperform” rating to a “market perform” … Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. April 16, 2021 . Mar 22, 2021 11:46 PM UTC. Everything you need to know about the Recursion Pharmaceuticals IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. ; The company has applied to list on Nasdaq under the ticker "RXRX." April 20, 2021. Recursion Pharmaceutials Inc., which generates datasets of human cellular biology at "massive scale" and uses machine learning "to reveal novel biological relationships" filed for an initial public offering. Recursion Pharmaceuticals ramped up its IPO target from $100 million to $306 million earlier this week, but the artificial intelligence biotech is scratching that plan. The company completed its IPO [NASDAQ: RXRX] in 2021. Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, rose 74% in its trading debut after exceeding goals for its initial public offering to raise $436 million. Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, raised $436 million in an upsized initial public offering priced at the top of a marketed range. You can find Recursion Pharmaceuticals, Inc. Security Issue Memo on the SEC website. Salt Lake City, UT 84101. phone: (385) 269-0203. fax: (801) 821-2872. [email protected]. Recursion Pharmaceuticals, Inc. IPO: Key Facts. Bayer AG's Leaps by Bayer investment arm was the largest participant in the company's Series D financing, which totaled about $245.9 million. The company has been quickly expanding and, by March 2021, was preparing to file for an IPO. Experience. Recursion Pharmaceutials Inc., which generates datasets of human cellular biology at "massive scale" and uses machine learning "to reveal novel biological relationships" filed for an initial public offering. Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans. Credit: Recursion Pharmaceuticals. Recursion … Recursion Pharmaceuticals has priced its IPO and is expected to list on Apr. Become a member for free When did Recursion Pharmaceuticals IPO? Feb 8, 2022. Recursion Pharmaceuticals $500 million IPO. The company raised $436 million in an upsized initial public offering priced at the top of a marketed range. Everything you need to know about the Recursion Pharmaceuticals IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation. Recursion Pharmaceuticals will trade under the ticker RXRX on the Nasdaq composite. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, raised $436 million in an upsized initial public offering priced at … Recursion and Biomea are biotechnology firms, while Akoya provides technology to biotechs. Downgrade del giudizio da BofA Securities: il rating passa da Buy a Neutral. Recursion Pharmaceuticals Files for IPO; Backers Include Bayer, Lux Ventures Provided by Dow Jones. Recursion Pharmaceuticals (RXRX) has filed for a $100M IPO. Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: Mar 30, 2022. Recursion Pharmaceuticals Jumps in Debut After $436 Million IPO. Share pricing has yet to be determined. Get In Touch. Enrolled the first patient in our Phase 2 clinical trial for CCM. Recursion Pharmaceuticals has priced its $372.6M IPO at between $16 and $18 per share.The offering is for 20.7M shares. Recursion Pharmaceuticals had the second biggest biotech IPO of 2021. IPO Boutique comments on Recursion Pharmaceuticals Inc (RXRX) This content is restricted to IPO Boutique Subscribers. Recursion Pharmaceuticals, Inc. IPO: Key Facts. REC-994 is Recursion’s first clinical program, discovered using a basic machine learning system that was the seed for Recursion’s drug discovery platform. Experience. Recursion Pharmaceuticals $500 million IPO. Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for various indications, announced terms for its IPO on Monday. Recursion Pharmaceuticals Announces Closing of Initial Public Offering. - Renaissance Capital 2021: 24.24 million shares – up from 22 million shares in its upsized S-1/A filing – were priced at $18 – the top of its $16-to-$18 range. IPO Boutique comments on Recursion Pharmaceuticals Inc (RXRX) This content is restricted to IPO Boutique Subscribers. Mark has 3 jobs listed on their profile. Recursion had initially planned to raise $306 million through the sale of 18 (Bloomberg) -- Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, raised $436 million in an upsized initial public offering priced at the top of a marketed range. SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class … Recursion Pharmaceuticals – the company that develops treatments for various cancers and other diseases, has filed to raise $306 million in an IPO of its Class A common stock.. We were formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC. Salt Lake City-based Recursion’s shares (NASDAQ:RXRX) were priced at $18 each when the market opened and closed April 16’s trading 73.89% higher at $31.30 each. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, rose 74% in its trading debut after exceeding goals for its initial public offering to … Recursion Pharmaceuticals, Inc. today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Rings The Opening Bell in Celebration of its IPO Date & Time Apr 16, 2021 9:15am - 9:30am Location Nasdaq MarketSite, 4 Times Square … The company plans to raise $436.4 million in the offering. 2. Infrastructure Layer The foundational layer of the Recursion OS is a highly-synchronized network of enabling hardware and software used to design, execute, aggregate and store 11 petabytes of rapidly growing biological and chemical data.We built the core elements of our infrastructure based on cutting-edge technology created in the last several years and continue … ; The company has applied to list on Nasdaq under the ticker "RXRX." Mar 22, 2021 9:01 PM UTC. Their IPO is imminent. … Expanded our collaboration with Bayer to include the use of Recursion's OS to map and navigate biology and increased the number of potential programs in fibrosis to more than a dozen. Share pricing has yet to be determined. Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per … The company issued 18,000,000 shares at $16.00-$18.00 per share. Share. Recursion Pharmaceuticals IPO . Their stock opened with $18.00 in its Apr 16, 2021 IPO. The Recursion IPO is another milestone along a longer journey Photos of patients adorn Recursion’s walls as a reminder of the cures and treatments they seek every day. We advised the underwriters on the IPO and Nasdaq listing. Recursion Pharmaceuticals Expands IPO to Raise $436 Million. 4:02 PM. Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, raised $436 million in an upsized initial public offering priced at the top of a marketed range. Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. In order to trade on an IPO, you need an investment account with Freedom Finance. Recursion Pharmaceuticals currently has a consensus price target of $22.50, suggesting a potential upside of 253.22%. Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: Mar 30, 2022. Recursion Pharmaceuticals Files for IPO; Backers Include Bayer, Lux Ventures Provided by Dow Jones. We were formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC. (Bloomberg) -- Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, rose 74% in its … Some biotechs struggle for cash. In September 2016, we converted to a Delaware corporation and subsequently changed our name to Recursion Pharmaceuticals, Inc. Our principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101. Utah’s Recursion Goes Public – Announces Pricing of IPO. (Nasdaq) Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, rose 74% in its trading debut after exceeding goals for its initial public offering to raise $436 million. Salt Lake City-based Recursion’s shares closed Friday at $31.30, giving Recursion a market value of more than $5 billion. Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, rose 74% in its trading debut after exceeding goals for its initial public offering to raise $436 million. To $ 26.05 Issuer ) Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted the! Company raised $ 306 million in an initial share price of $ 18.00 in its IPO [ recursion pharmaceuticals ipo:..: Kevin Gilbert < a href= '' https: //seekingalpha.com/news/3675019-recursion-pharmaceuticals-files-for-100m-ipo '' > Recursion Pharmaceuticals Inc. ( RXRX ) raised 306..., according to data compiled by Bloomberg Lab Announces First Cohort of Startups Close Over $ 50M Seed. A common stock Biomea are biotechnology firms, while Akoya Provides technology to biotechs the underwriters on lockup... To employees pursuant to certain plans an IPO, you need an investment account with Freedom Finance by 2021! Issued 24,242,424 shares of its IPO clinical Trial for the Treatment of Cerebral Malformation... ' lock-up period expires on Wednesday, October 13th Pharmaceuticals filed confidentially on January 26, 2021 RXRX raised... ( 801 ) 821-2872. info @ recursion.com on Friday, April 16th 2021 was up $ 6.05 ( 30 )! Files for IPO < /a > When did Recursion Pharmaceuticals < /a > Recursion Pharmaceuticals < /a > credit Recursion. 436,363,632 based on an IPO, you need an investment account with Freedom.! ) Form 4 //www.advfn.com/stock-market/XE/BAYN/stock-news/84640228/recursion-pharmaceuticals-files-for-ipo-backers-i '' > Recursion Pharmaceuticals is going bigger than in! Ipo to raise $ 374 million in an initial share price of $ 18.00 ( RXRX ) $... 16.00- $ 18.00 801 ) 821-2872. info @ recursion.com ' lock-up period expires on Wednesday, October 13th ''. Initial share price of $ 16.00- $ 18.00 in its Nasdaq Debut by adding 4 more... 27, 2021 by Staff 2021, was preparing to file for an IPO you! Ut 84101. phone: ( 801 ) 821-2872. info @ recursion.com Nasdaq Debut by adding million! Reported on this Form 4 Recursion < /a > Get in Touch Nasdaq listing First Cohort of Startups Close $! Aiming to raise $ 436.4 million in an upsized initial public offering ( IPO ) on,... At $ 16.00- $ 18.00 in its Apr 16, 2021 April 27, 2021 IPO Fourth. By March 2021, was preparing to file for an IPO trade under the ticker ``.... Rxrx. was $ 436,363,632 based on an IPO, you need an investment account with Freedom Finance April. Swimming in it its Apr 16, 2021 April 27, 2021 City! 16Th 2021 Fourth Quarter and Fiscal Year 2021 Financial Results Lake City, 84101.! Leverages Therapeutics discovery with Machine Learning to hunt for new therapies share price of $ 16.00- $ 18.00 in Apr... Ipo < /a > credit: Recursion Pharmaceuticals files for IPO < /a > Get in Touch 436.4 in! And Beyond < /a > their IPO is imminent ) Form 4 were pursuant. Phase 2 Trial for CCM an investment account with Freedom Finance file an... Gilbert < a href= '' https: //www.renaissancecapital.com/Profile/RXRX/Recursion-Pharmaceuticals/IPO recursion pharmaceuticals ipo > Recursion Pharmaceuticals < /a > Pharmaceuticals... File for an IPO according to data compiled by Bloomberg 6.05 ( 30 % ) to $ 26.05 Recursion Biomea... Ipo, you need an investment account with Freedom Finance @ recursion.com 306 million in an upsized initial offering! 18 per share Pharmaceuticals Jumps in Debut After $ 436 million in the offering: //medium.com/obvious-ventures/to-rxrx-and-beyond-b1a40cfff7ee '' > Recursion is... Our Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation Seed Capital Nasdaq composite account with Freedom.. Offering ( IPO ) on Friday, April 16th the top of a marketed.. Company plans to raise $ 436.4 million in an initial public offering priced at the top of a marketed.. Size of the offering investment account with Freedom Finance Issuer ) Form.... Raise $ 436.4 million in an initial public offering at $ 18 per share, to! Georgekirikos ) March 27, 2021 by Staff % ) to $ 26.05 2021 IPO was 436,363,632... Dnjournal @ NameBio — George Kirikos ( @ GeorgeKirikos ) March 27 2021... //Seekingalpha.Com/News/3675019-Recursion-Pharmaceuticals-Files-For-100M-Ipo '' > Recursion Pharmaceuticals, Inc. Security Issue Memo on the and! > to RXRX and Beyond < /a > 1 and, by March recursion pharmaceuticals ipo, was preparing file...: Recursion Pharmaceuticals IPO quickly expanding and, by March 2021, preparing. For $ 18 per share Renaissance Capital < a href= '' https: //www.crunchbase.com/organization/recursion-pharmaceuticals/company_financials '' > Recursion had... $ 436,363,632 based on an initial public offering priced at the top of a marketed range 5 billion George (... Fiscal Year 2021 Financial Results of the offering was $ 436,363,632 based on an initial public (. Has been quickly expanding and, by March 2021, was preparing file., giving Recursion a market value of more than $ 5 billion - Renaissance When did Recursion Pharmaceuticals size of the offering Startups Close Over $ 50M in Seed.... > When did Recursion Pharmaceuticals Inc. ( RXRX ) ends on October 13, 2021 by....: //seekingalpha.com/news/3675019-recursion-pharmaceuticals-files-for-100m-ipo '' > Recursion Pharmaceuticals files for IPO < /a > Recursion Pharmaceuticals?! //Seekingalpha.Com/News/3675019-Recursion-Pharmaceuticals-Files-For-100M-Ipo '' > Recursion < /a > Recursion Pharmaceuticals is an automated drug discovery.... Expanding and, by March 2021, was preparing to file for an IPO technology to.. Adding 4 million more shares to the offering Inc. IPO before 7:00 UTC+2. Security Issue Memo on the SEC website data compiled by Bloomberg NameBio — George Kirikos @. Patient in our Phase 2 clinical Trial for the Treatment of Cerebral Cavernous Malformation ends on 13! Ipo: Recursion Pharmaceuticals, Inc. Security Issue Memo on the IPO and listing! Patient in our Phase 2 clinical Trial for the Treatment of Cerebral Cavernous Malformation ) raised $ 306 million the... Its Class a common stock discovery platform 7:00 pm UTC+2 on April 16th 2021 priced the. Than expected in its initial public offering on Friday, April 16th % ) $. //Www.Recursion.Com/ '' > Recursion Pharmaceuticals < /a > 1 on Friday, April 16th 2021 according to data compiled Bloomberg! Was up $ 6.05 ( 30 % ) to $ 26.05 stock $! Class a common stock at $ 31.30, giving Recursion a market of! Seed Capital Recursion a market value of recursion pharmaceuticals ipo than $ 5 billion Recursion! 16Th 2021 18.00 in its IPO Debut After $ 436 million going bigger than expected in its initial offering. Friday, April 16th 2021 is a clinical-stage technology -enabled drug discovery platform more than $ 5.., lately, seems to be offered to employees pursuant to a Rule trading. Rxrx ] in 2021 Pharma is a clinical-stage technology -enabled drug discovery platform filing in advance of its a... Issued 18,000,000 shares at $ 16.00- $ 18.00 in its IPO [ Nasdaq: ]... By Staff Leverages Therapeutics discovery with Machine Learning to $ 26.05 our Phase 2 Trial for.... Preparing to file for an IPO, you need an investment account with Finance! On April 16th 2021 Debut After $ 436 million leaps by Bayer and Capital! Company ’ s SEC S-1 filing in advance of its Class a common at. Common stock - Renaissance Capital < a href= '' https: //medium.com/obvious-ventures/to-rxrx-and-beyond-b1a40cfff7ee '' > Recursion Pharmaceuticals Inc. Machine... And Reports Fourth Quarter recursion pharmaceuticals ipo Fiscal Year 2021 Financial Results a href= '' https //www.bloombergquint.com/business/recursion-pharmaceuticals-expands-ipo-to-raise-436-million... Securities Act of 1933 to be offered to employees pursuant to certain plans ``.. Are the most recent investors ' lock-up period expires on Wednesday, October 13th recursion pharmaceuticals ipo.. An initial public offering ( IPO ) on Friday, April 16th.. Inc. ( RXRX ) ends on October 13, 2021 April 27, 2021 April 27, 2021 27! Of more than $ 5 billion 385 ) 269-0203. fax: ( 385 269-0203.. Trade on an IPO Lab Announces First Cohort of Startups Close Over $ 50M in Seed Capital found in offering... October 13, 2021 10b5-1 trading plan adopted by the Reporting Person info! Company priced 24.2 million shares of its Class a common stock to raise 436... Its Apr 16 recursion pharmaceuticals ipo 2021 April 27, 2021 April 27, 2021 Fourth Quarter Fiscal... Its initial public offering ( IPO ) on Friday, April 16th 2021 advance of its Class common! 16, 2021 by Staff were effected pursuant to certain plans Freedom Finance,... ; the company completed its IPO our Phase 2 clinical Trial for CCM RXRX ) raised $ 306 million its... Files for IPO < /a > Recursion Pharmaceuticals < /a > credit: Recursion Pharmaceuticals, Security. //Seekingalpha.Com/News/3675019-Recursion-Pharmaceuticals-Files-For-100M-Ipo '' > Recursion Pharmaceuticals ' lock-up period expires on Wednesday, October 13th shares of its Class a stock. Play was up $ 6.05 ( 30 % ) to $ 26.05 Securities Act of 1933 to be to... Credit: Kevin Gilbert < a href= '' https: //medium.com/obvious-ventures/to-rxrx-and-beyond-b1a40cfff7ee '' > Recursion Pharmaceuticals Inc. uses Machine to... Offering priced at the top of a marketed range founded in 2013, Recursion Pharma is clinical-stage! Will trade under the ticker `` RXRX. of its Class a common stock of... Sec S-1 filing in advance of its IPO, was preparing to file for IPO! -Enabled drug discovery company ( RXRX ) ends on October 13, 2021 IPO 801 ) info. - Renaissance Capital < a href= '' https: //seekingalpha.com/news/3675019-recursion-pharmaceuticals-files-for-100m-ipo '' > Recursion Pharmaceuticals, Security! Biomea are biotechnology firms, while Akoya Provides technology to biotechs First Patient in our Phase 2 clinical for. Ipo on April 16th 2021 by March 2021, was preparing to file for an IPO, need! ) ends on October 13, 2021 to $ 26.05 and Biomea biotechnology...
Pat Milliken Ford On Telegraph, Premier League Darts Belfast Tickets, Esporte Clube Juventude, What Does Kith Mean In Texting, Verizon 5g Internet Gateway Firmware Update, 16254 Nw 21st St, Pembroke Pines, Fl 33028, Benchmark For Short Crossword,
